生物制药公司VistaGen Therapeutics公布了其第一财季业绩,数据显示,公司净亏损达到1303万美元,折合每股亏损0.30美元。这一财务表现反映出公司在研发投入与运营成本上的持续支出,而尚未实现盈利。尽管市场对其治疗领域的前景存在期待,但当前财报显示,该公司仍处于亏损扩张阶段。
生物制药公司VistaGen Therapeutics公布了其第一财季业绩,数据显示,公司净亏损达到1303万美元,折合每股亏损0.30美元。这一财务表现反映出公司在研发投入与运营成本上的持续支出,而尚未实现盈利。尽管市场对其治疗领域的前景存在期待,但当前财报显示,该公司仍处于亏损扩张阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.